T1	Treatment 14 32	placebo-controlled
T2	Treatment 50 74	ganitumab or conatumumab
T3	Treatment 278 289	bevacizumab
T4	Treatment 294 306	aflibercept.
T5	Treatment 347 358	conatumumab
T6	Treatment 429 438	ganitumab
T7	Treatment 734 786	fluoropyrimidine- and oxaliplatin-based chemotherapy
T8	Treatment 824 917	intravenous FOLFIRI plus conatumumab 10 mg/kg (Arm A), ganitumab 12 mg/kg (Arm B), or placebo
T9	Treatment 1453 1476	CONCLUSIONS Conatumumab
T10	Treatment 1482 1509	not ganitumab, plus FOLFIRI
